Trial Condition(s):
Hypertension
The Real-Life Efficacy and Safety of Telmisartan in Patients with Arterial Hypertension (METABOLIC)
Bayer Identifier:
12729
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
The main purpose of this study is to asses the efficacy and safety of telmisartan, with the special attention on the influence of telmisartan on selected metabolic parameters of patients.
Inclusion Criteria
- Age over 18 - Untreated or ineffectively treated arterial hypertension
Exclusion Criteria
- Cholestatic disorders and severe hepatic failure - Allergy to telmisartan - Pregnancy and lactation period
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | Status | |
|---|---|---|
Locations Investigative Site Many locations, Croatia | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many locations, Slovenia | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many locations, Poland | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many locations, Slovakia | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Asses the Efficacy and Safety of Telmisartan, With the Special Attention on the Influence of Telmisartan on Selected Metabolic Parameters of Patients
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Efficacy and safety of the treatment with telmisartan reported by the physicianTimeframe: At the both of planned control visits. (Approx. interval between visits 3 months)
Secondary Outcome
- Changes in metabolic parameters in telmisartan treated patientsTimeframe: At the both of planned control visits. (Approx. interval between visits 3 months)
Additional Information
Copyright © Bayer
Powered by
